On November 22, 2022 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences (Press release, Kura Oncology, NOV 22, 2022, View Source [SID1234624341]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A fireside chat at the Evercore ISI HealthCONx Conference at 12:35 p.m. ET / 9:35 a.m. PT on November 29, 2022; and

A fireside chat at the JMP Securities Hematology and Oncology Summit at 12:20 p.m. ET / 9:20 a.m. PT on December 7, 2022.
Audio webcasts of both fireside chats will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available following both events.